<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> FR88720-0003 </DOCNO><DOCID>fr.7-20-88.f2.A1002</DOCID><TEXT><ITAG tagnum="94"><ITAG tagnum="69"><ITAG tagnum="50">DEPARTMENT OF HEALTH AND HUMAN SERVICES</ITAG><ITAG tagnum="18">Food and Drug Administration</ITAG><ITAG tagnum="52">21 CFR Part 520 </ITAG><ITAG tagnum="56">Oral Dosage Form New Animal Drugs Not Subject to Certification; CefadroxilPowder for Oral Suspension </ITAG><ITAG tagnum="10"><T2>AGENCY: </T2>Food and Drug Administration.</ITAG><ITAG tagnum="10"><T2>ACTION: </T2>Final rule.  </ITAG><ITAG tagnum="10"><T2>SUMMARY: </T2>The Food and Drug Administration (FDA) is amending theanimal drug regulations to reflect approval of a new animal drug application(NADA) filed by Fort Dodge Laboratories, Inc., providing for safe and effectiveuse of cefadroxil powder for oral suspension for treating certain genitourinarytract and skin and soft tissue infections of dogs, and skin and soft tissueinfections of cats.</ITAG><ITAG tagnum="10"><T2>EFFECTIVE DATE: </T2>July 20, 1988.</ITAG><ITAG tagnum="10"><T2>FOR FURTHER INFORMATION CONTACT:</T2>Sandra K. Woods, Center for VeterinaryMedicine (HFV-114), Food and Drug Administration, 5600 Fishers Lane, Rockville,MD 20857, 301-443-3420.</ITAG><ITAG tagnum="10"><T2>SUPPLEMENTARY INFORMATION: </T2>Fort Dodge Laboratories, Inc., Divisionof American Home Products Corp., 800 Fifth St. NW., Fort Dodge, IA 50501-0508,filed NADA 140-684 providing for safe and effective use of Cefa-Drops<T4>#</T4> (cephadroxil powder for oral suspension). When reconstitutedto an aqueous suspension, the drug is given orally to dogs for treatinggenitourinary tract infections (cystitis) caused by susceptible strainsof <T3>Escherichia coli, Proteus mirabilis, </T3>and <T3>Staphylococcus aureus; </T3>and skin and soft tissue infections includingcellulitis, pyoderma, dermatitis, wound infections, and abscesses causedby susceptible strains of <T3>Staphylococcus aureus. </T3>The reconstituted drug is given orallyto cats for treating skin and soft tissue infections including abscesses,wound infections, cellulitis, and dermatitis caused by susceptible strainsof <T3>Pasteurella multocida, Staphylococcus aureus, Staphylococcus epidermidis,</T3>and <T3>Streptococcus </T3>spp. The NADA is approved and the regulations are amended by adding new andSection;520.315 to reflect this approval. The basis of approval is discussed inthe freedom of information summary. In accordance with the freedom of information provisions of Part 20 (21CFR Part 20) and andSection; 514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)),a summary of safety and effectiveness data and information submitted tosupport approval of this application may be seen in the Dockets ManagementBranch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 FishersLane, Rockville, MD 20857, from 9 a.m. to 4 p.m., Monday through Friday.The agency has determined under 21 CFR 25.24(d)(1)(iii) that this actionis of a type that does not individually or cumulatively have a significanteffect on the human environment. Therefore, neither an environmental assessmentnor an environmental impact statement is required. <ITAG tagnum="84">List of Subjects in 21 CFR Part 520 </ITAG>Animal drugs.Therefore, under the Federal Food, Drug, and Cosmetic Act and under authoritydelegated to the Commissioner of Food and Drugs and redelegated to theCenter for Veterinary Medicine, Part 520 is amended as follows: <ITAG tagnum="56">PART 520_ORAL DOSAGE FORM NEW ANIMAL DRUGS NOT SUBJECT TO CERTIFICATION</ITAG>1. The authority citation for 21 CFR Part 520 continues to read as follows:<ITAG tagnum="21"><T4>Authority: </T4>Sec. 512(i), 82 Stat. 347 (21 U.S.C. 360b(i)); 21 CFR5.10 and 5.83.</ITAG>2. Part 520 is amended by adding new andSection; 520.315 to read as follows:<ITAG tagnum="80">andSection; 520.315 </ITAG><ITAG tagnum="89">Cefadroxil powder for oral suspension. </ITAG>(a) <T3>Specifications. </T3>Cefadroxil powder is reconstituted to form a 50milligram-per-milliliter aqueous suspension. (b) <T3>Sponsor. </T3>See No. 000856 in andSection; 510.600(c) of this chapter.(c) <T3>Conditions of use. </T3>(1) For use in dogs as follows: (i) <T3>Indications for use. </T3>For treating genitourinary tract infections(cystitis) caused by susceptible strains of <T3>Escherichia coli, Proteus mirabilis, </T3>and <T3>Staphylococcus aureus; </T3>and skin and soft tissue infections includingcellulitis, pyoderma, dermatitis, wound infections, and abscesses causedby susceptible strains of <T3>Staphylococcus aureus. </T3>(ii) <T3>Amount. </T3>10 milligrams per pound of body weight, twice daily. (2) For use in cats as follows: (i) <T3>Indications for use. </T3>For treating skin and soft tissue infectionsincluding abscesses, wound infections, cellulitis, and dermatitis causedby susceptible strains of <T3>Pasteurella multocida, Staphylococcus aureus, Staphylococcus epidermidis,</T3>and <T3>Streptococcus </T3>spp. (ii) <T3>Amount. </T3>10 milligrams per pound of body weight, once daily. (3) <T3>Limitations. </T3>Discard unused portion of reconstituted product after14 days. Treatment should continue for 48 hours after animal is afebrileor asymptomatic. If no response after 3 days, discontinue treatment andreevaluate therapy. Not for use in animals raised for food production.Safe use in pregnant or breeding animals has not been established. Federallaw restricts this drug to use by or on the order of a licensed veterinarian.<ITAG tagnum="21">Dated: July 12, 1988. </ITAG><ITAG tagnum="6">Richard H. Teske, </ITAG><ITAG tagnum="4">Deputy Director, Center for Veterinary Medicine. </ITAG><ITAG tagnum="40">[FR Doc. 88-16298 Filed 7-19-88; 8:45 am] </ITAG><ITAG tagnum="68">BILLING CODE 4160-01-M </ITAG></ITAG></ITAG></ITAG></TEXT></DOC>